◂ Announcements

Jul 12, 2019ACQUISITION

Recordati to acquire worldwide rights to Signifor and Osilodrostat from Novartis

Recordati signed an agreement with Novartis to acquire worldwide rights to Signifor and Osilodrostat for $390 million, with Novartis supplying products during a transitional period.

Value

$390.0M

Status

Announced

ProductsSigniforSignifor LAROsilodrostat

CompaniesNovartis target Recordati acquirer

“Upon completion of transaction a consideration of $390 million will be due to Novartis.”reuters.com

1 source
reuters.comRecordati To Acquire Worldwide Rights To Signifor And Osilodrostat (LCI699)Jul 12, 2019

Summarized from public sources; check the original articles before acting on it.

More from Novartis

profile ▸

Jun 30, 2022NEW FACILITYKalwe, Mumbai, Maharashtra, India200 jobsops 30 Jun 2022
Sandoz inaugurates oncology manufacturing plant in Kalwe, India
Sandoz Novartis partner indiamedtoday.com
May 20, 2021EXPANSIONKundl, Austria, Austria$122.0M
Sandoz invests $183M in European antibiotic production expansion
Sandoz Novartis partner endpoints.news
Sep 1, 2020ACQUISITIONMarburg, Germany, Germany300 jobs
BioNTech to acquire Novartis GMP manufacturing site in Marburg, Germany
BioNTech acquirer Novartis target biontech.com
Nov 18, 2019ACQUISITIONZürich, Switzerland, Switzerland
Biofourmis acquires Biovotion and inks commercialization deal with Novartis
Novartis partner Biofourmis acquirer mobihealthnews.com
Oct 21, 2019CONTRACT
SomaLogic and Novartis sign ten-year proteomics agreement
Novartis customer SomaLogic supplier globenewswire.com
Feb 19, 2019EXPANSIONDurham, North Carolina, United States$60.0M200 jobsops Q3 2020
AveXis expands gene therapy manufacturing facility in North Carolina with additional $60M investment
AveXis Novartis investor fiercepharma.com

Loading…

Recordati to acquire worldwide rights to Signifor and Osilodrostat from Novartis · Endata